Resource for Your Office: Medical Exception Form
Establish the medical necessity of MAVYRET.
Download FormAI-generated imagery. Not real patients.
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).1
98%
Medicaid formulary coverage under the pharmacy benefit as of February 2025.2
Available for Majority of National Commercial and Medicare Part D Plans2
51% preferreda National Commercial and 65% preferreda Medicare Part D formulary coverage under the pharmacy benefit as of February 2025.2
aMAVYRET is on a preferred tier or otherwise has preferred status on the plan’s formulary.
bMAVYRET is the only product in the DAA market basket on formulary designated by the insurer.
AbbVie Is the Exclusive Medicaid Partner In 80% of States With Elimination Programs as of May 20253
Louisiana, Michigan, Missouri, Texas, and Washington state Medicaid have partnered with pharmaceutical manufacturers with a goal to eliminate HCV. MAVYRET has exclusiveb coverage in Michigan, Missouri, Texas, and Washington state Medicaid.
#1 Prescribed HCV Product for Over 5 Years
Based on data from IQVIA, week ending 1/12/18 to 2/28/25.4
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
Exclusive is defined as MAVYRET is the only product in the Therapeutic class on Formulary. Preferred is defined as MAVYRET is on the plan's Preferred Formulary. Available is defined as MAVYRET is available through Medical Exception for Diagnosis.
Eligible patients with commercial insurance may pay as little as $5 or less per monthc
Your patients may be eligible to receive MAVYRET at no cost if they have been prescribed MAVYRET and have limited or no health insurance coverage. If your patients have insurance, we will review their qualifying financial need based on a combination of their insurance coverage, household income, and out-of-pocket medical expenses during the application process.
Resource for Your Office: Medical Exception Form
Establish the medical necessity of MAVYRET.
Download FormMAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and posttreatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Risk of Hepatic Decompensation/Failure in Patients with Evidence of Advanced Liver Disease
Risk of Reduced Therapeutic Effect Due to Concomitant Use of MAVYRET with Certain Drugs
Most common adverse reactions observed with MAVYRET:
MAVYRET oral pellets are dispensed in unit-dose packets. Each packet contains 50 mg glecaprevir/20 mg pibrentasvir.
US-MAVY-250347